Peter Soparkar - Mar 15, 2023 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Chief Operating Officer
Signature
Peter Soparkar, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
ADVM
Transactions as of
Mar 15, 2023
Transactions value $
-$10,442
Form type
4
Date filed
3/17/2023, 06:02 PM
Previous filing
Mar 3, 2023
Next filing
Mar 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADVM Common Stock Sale -$10.4K -13.4K -4.78% $0.78 266K Mar 15, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain performance stock units.
F2 Includes 6,000 shares purchased on November 18, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, as amended and restated.